Literature DB >> 8737693

Resectional surgery in carcinoma of the oesophagus and cardia: what influences long-term survival?

D A Sharpe1, K Moghissi.   

Abstract

OBJECTIVE: Our objectives were to determine factors which influence survival after resectional surgery in patients with cancer of the oesophagus and cardia. PATIENTS AND
METHOD: 562 consecutive patients with primary cancer of the oesophagus or gastric cardia (oesophago-gastric junction) undergoing resectional surgery and reconstruction of the oesophagus were studied. Operative approach depended on tumour location, the aim being complete resection of the tumour and associated lymph nodes. Postoperative staging was based on tumour, nodes and metastasis (TNM) classification.
RESULTS: There were 342 males and 220 females, aged 61.8 +/- 12.8 years. Histology of the tumours was: squamous cell carcinoma 49%, adenocarcinoma 47.5% and other tumours 3.5%. The location of tumours within the oesophagus was: cervical (n = 32), upper thoracic (n = 18), middle thoracic (n = 241) and lower thoracic and gastric cardia (n = 271). Of the tumours 16% were stage I, 10% stage II and 74% stage III. Hospital mortality rate was 9% overall, significantly higher in cervical tumours (cervical tumours versus lower and or middle oesophageal tumours: P < 0.05), the elderly (age > 75 years versus age < 75 years: P < 0.05) and stage III disease (stage III versus stage I: P < 0.001). The overall 5-year survival rate was 18%. There was no correlation between tumour histology, location or type of operation and long-term survival. Survival disease-free for 5 years or more was 73% for stage I, 15.8% for stage II and 6% for stage III. The only significant correlation was between the stage of disease and long-term survival (stage I versus stage III P < 0.001, stage I versus stage II P < 0.05).
CONCLUSIONS: Immediate results are affected by a number of factors but long-term survival is related entirely to the stage of the tumour.

Entities:  

Mesh:

Year:  1996        PMID: 8737693     DOI: 10.1016/s1010-7940(96)80095-9

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  8 in total

1.  Role of photodynamic therapy in the palliation of obstructing esophageal cancer.

Authors:  Hyeon Young Yoon; Young Koog Cheon; Hye Jin Choi; Chan Sup Shim
Journal:  Korean J Intern Med       Date:  2012-09-01       Impact factor: 2.884

Review 2.  Transhiatal versus transthoracic esophagectomy for esophageal cancer.

Authors:  J Camilo Barreto; Mitchell C Posner
Journal:  World J Gastroenterol       Date:  2010-08-14       Impact factor: 5.742

Review 3.  [Management of delayed complications after esophagectomy].

Authors:  A Beham; S Dango; B M Ghadimi
Journal:  Chirurg       Date:  2015-11       Impact factor: 0.955

4.  Effect of postoperative course on midterm outcome after esophageal resection for cancer.

Authors:  Themistokles Chamogeorgakis; Faiz Bhora; Ioannis Toumpoulis; Andy Nabong; Cliff Connery
Journal:  Proc (Bayl Univ Med Cent)       Date:  2013-07

5.  Photodynamic therapy: establishing its role in palliation of advanced esophageal cancer.

Authors:  Jong-Jae Park
Journal:  Korean J Intern Med       Date:  2012-09-01       Impact factor: 2.884

6.  Optimising surgical management of elderly cancer patients.

Authors:  Hodigere Sripathy Jois Ramesh; Daniel Pope; Roberto Gennari; Riccardo A Audisio
Journal:  World J Surg Oncol       Date:  2005-03-23       Impact factor: 2.754

7.  Role and new perspectives of transforming growth factor-alpha (TGF-alpha) in adenocarcinoma of the gastro-oesophageal junction.

Authors:  A D'Errico; C Barozzi; M Fiorentino; R Carella; M Di Simone; L Ferruzzi; S Mattioli; W F Grigioni
Journal:  Br J Cancer       Date:  2000-02       Impact factor: 7.640

8.  Evaluation on Short-Term Therapeutic Effect of 2 Porphyrin Photosensitizer-Mediated Photodynamic Therapy for Esophageal Cancer.

Authors:  Huilong Liu; Yanfang Liu; Li Wang; Xinjian Ruan; Fei Wang; Dandan Xu; Jing Zhang; Xiaoyan Jia; Duanqi Liu
Journal:  Technol Cancer Res Treat       Date:  2019-01-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.